Last Updated on October 10, 2024 by The Health Master
The Indian Pharmacopoeia Commission (IPC) has flagged a drug safety alert to the Drugs Controller General of India (DCGI), revealing that minoxidil is associated with an adverse event known as folliculitis.
IPC is the National Coordination Centre (NCC) for the Pharmacovigilance Program of India (PvPI).
Minoxidil topical solution has been approved in India for the treatment of hair loss in men.
It has also been authorized by the US Food and Drug Administration (USFDA) for the treatment of hair loss in both men and women.
Folliculitis is often caused when hair follicles are infected with bacteria like Staphylococcus aureus (staph).
It may also be caused by viruses, fungi, parasites, medications, or physical injury.
However, healthcare practitioners say that Minoxidil does not cause folliculitis. The scalp has to be examined and a proper diagnosis has to be done for further treatment.
Dr. Reddy’s Laboratories launched the prescription drug Minoxidil topical solution USP 2% and 5% for the treatment of female pattern hair loss (FPHL) in September 2021 under the brand names Mintop 2% and Mintop Eva 5%, respectively.
The DCGI had given the first-ever approval for the use of Minoxidil topical solution USP 2% and 5% for the treatment of female pattern hair loss (FPHL) in India.
Minoxidil topical solution is available as a first-line treatment option for FPHL in India. While minoxidil topical solution has been approved in India for the treatment of male pattern baldness, there are presently no other drugs approved for the treatment of FPHL.
Female pattern hair loss is the most common cause of hair loss in women and its prevalence increases with advancing age, often leading to psychological distress.
The launch follows the first-ever approval of the additional indication by the Central Drugs Standard Control Organization (CDSCO) in India for the use of minoxidil topical solution USP 2% and 5% for the treatment of FPHL.
Minoxidil topical solution will become available as a first-line treatment option for FPHL in India.
While minoxidil topical solution has been approved in India for the treatment of alopecia in men (male pattern baldness), there were no other drugs approved for the treatment of FPHL in India.
PvPI was implemented by the CDSCO in July 2010 across the country.
Since then, IPC has been mandated to establish clinical evidence between the drug and the ADR event through a robust system of causality assessment.
IPC alert: About Norfloxacin induced skin hyperpigmentation
IPC alerts about Cefoperazone induced coagulopathy
IPC flags safety alert against immunosuppressive drug Tacrolimus
IPC flags safety alert against Blood Pressure drug, Losartan
IPC flags safety alert against most common Drug Ibuprofen – NSAID
IPC flags safety alert against Covid-19 drug Remdesivir
USFDA issues Form 483 with 8 observations to Jubilant
NPPA releases 5th list of draft ceiling prices for 69 formulations
DCOIWA to conduct workshops on Drugs & Medical Devices
US Court dismisses cancer linkage associated with Ranitidine
USFDA approves this lung cancer drug
International drug racket busted in Hyderabad, two held
Drug alert: 83 out of 1487 samples declared as NSQ in November 20222
FDA: Patients cannot be forced to buy medicines from hospital-attached pharmacies
Pharmacy education needs to adopt 2D, 3D format for lectures
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
